Pulmonx Q3 2026 Earnings Conference Call - PULMONX CORP

Explicit Guidance:

• Full Year 2026 Revenue: Reiterated guidance range of $90 million to $92 million; management expects Q4 growth to continue, implying a potential exit rate of double-digit growth for the quarter.
• Full Year 2026 Operating Expenses: Expected to fall between $108 million and $109 million (inclusive of ~$14 million non-cash stock-based compensation).
• Full Year 2026 Gross Margin: Expected to be approximately 77% (up from 76% in Q3), driven by mix benefits and supply chain efficiencies persisting through year-end.
• Full Year 2026 Cash Burn: Expected to burn roughly $22 million, representing a 30% reduction from 2025 cash burn.
• Long-term Growth Commitment: Management remains committed to sustaining double-digit growth for the company moving forward, though no specific 2027 numerical guidance is provided yet.
• Non-GAAP Adjusted EBITDA: While not providing full-year guidance, the company noted progress toward profitability and a pathway to cash flow break-even driven by operating leverage.

Business-Segment Outlook:

• U.S. Commercial: Confidence in continued growth as the rebuilt sales team ramps productivity; substantially all open U.S. sales positions filled; focus remains on "near-to-far" strategy, high-value valve programs, and direct-to-patient efforts in established geographies.
• International (Non-China): Excluding China, international markets grew ~9% and are expected to remain strong; China commercial activity to resume shipments to distributors by early next year (Q4 2026 or Q1 2027), representing an estimated 2% of total business.
• New Product (AeroSeal): Commercial launch expected in Europe in 2027 as a "limited launch"; material revenues anticipated in 2028. The program is projected to expand the Total Addressable Market (TAM) by roughly 20% globally.
• Pipeline/Clinical: Enrollment in the Convert2 IDE trial (AeroSeal) on track to complete in the back half of 2027.
• Sales Force Structure: No immediate central plan for broad sales expansion; territory additions will be opportunistic only when size/complexity warrants or geography is exceptionally broad, with a focus on promoting junior reps (TAMs) to quota-carrying roles.

Market and Competitive Outlook:

• Demand Trends: Positive market engagement observed at specialty society meetings (European Respiratory Society, AABIP); significant interest in patient pathways, multidisciplinary COPD management, and emerging uses of endobronchial valves.
• Pricing/Costs: Operating expenses held steady despite growth; cost structure reduced by 10% without impacting commercial/R&D investments. Management expects to maintain current cost levels, with only minor increases anticipated due to inflation.
• Competitive Positioning: Strategy shift toward focusing on fewer, higher-impact initiatives to accelerate growth; emphasis on "same-store sales" and reactivating existing accounts over pure new account acquisition, as newer reps have shown success in reigniting dormant accounts.

Macro / Industry Outlook:

• FX Impact: Reported revenue growth was consistent on both reported and constant currency bases; Q3 international growth was 6% on a constant currency basis.
• Regulatory/Tariffs: China registration certificate renewed; administrative challenges and tariff discussions previously impacted revenue, but current outlook assumes stable execution.
• Economic Environment: No specific macroeconomic downturns cited as headwinds; management confidence is driven by internal execution and market fundamentals rather than external macro factors.

Strategic Initiatives:

• Clinical Expansion: Continued advancement of the LIBERATE pivotal trial data (5-year follow-up) and the Convert2 IDE trial for AeroSeal to validate long-term efficacy and market expansion.
• Capital Structure: Credit facility restructuring in early 2026 extended maturity to 2031; facility includes access to an additional $20 million in undrawn capital subject to revenue milestones.
• Operational Restructuring: Cost reduction efforts initiated at the start of the year are yielding results; focus on disciplined execution and operating leverage to reach cash flow break-even.

Risks and Headwinds to Outlook:

• Revenue Mix: China remains a distributor market with lumpy and unpredictable revenue patterns compared to direct markets; expected to be a modest drag on gross margins (below 75%) while maintaining operating profitability.
• Execution Risk: Salesforce tenure remains relatively junior (median tenure ~1.2 years); variability exists in the time required to bring new reps to full productivity.
• Clinical/Trial Timing: AeroSeal commercialization timelines depend on Convert2 IDE enrollment completion in the back half of 2027 and subsequent regulatory approvals.
• External Factors: General risks associated with clinical trial outcomes, regulatory approvals, and the possibility of actual results differing from forward-looking assumptions (standard safe harbor language applies).

Management Tone on the Future:

• Confidence Level: High confidence and "greater conviction" in the current strategy, citing the return to year-over-year revenue growth and significant operating leverage improvements (EBITDA loss reduced nearly 60% YoY).
• Trend: Management views the Q3 results as a confirmation that the "near-to-far" strategy is working, with a clear trajectory toward sustained double-digit growth and profitability.
• Cautions: While bullish, management exercised caution on 2027 numerical guidance, stating it is "premature" to lock in timeframes immediately after returning to growth, deferring details to the next earnings call.

Miscellaneous:

• Balance Sheet Strength: Ended Q3 2026 with $52.7 million in cash and cash equivalents.
• Share Count/Dividends: No mention of specific share count targets, dividend policies, or buyback programs in the forward-looking sections.
• Geographic Mix: U.S. represents 64% of business; Europe 33%; Asia Pacific 3% (China ~2% when active).